Celyad Archives

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is…

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I…

November 12, 2019 - 2 minutesmins - By Jonathan Smith

cancer treatments personalized technology

In Depth 15 Oct 2019

Four New Technologies That Will Change Cancer Treatment

New approaches to tame the immune system in the fight against cancer are getting us closer to a future where cancer becomes a curable disease. Personalized vaccines, cell therapy, gene…

October 15, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2018

CAR-T Promise for Patients with Solid Tumors

A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results against solid tumors in two Phase I trials, including one trial that did not include add-on…

November 14, 2018 - 3 minutesmins - By Jonathan Smith

Interview 13 Jun 2018

CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead

CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead…

June 13, 2018 - 5 minutesmins - By Alexander Burik

News and Trends 23 May 2018

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Update (23/05/2018): Investors have fully subscribed Celyad's global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of…

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 19 Apr 2018

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. …

April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jan 2018

Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad

Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave but Celyad misses it. Shortly after the mega-acquisition of Kite by…

January 23, 2018 - 2 minutesmins - By Evelyn Warner

News and Trends 29 Aug 2017

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter…

August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in…

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

Celyad heart failure cell therapy C Cure

News and Trends 11 May 2017

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient's own stem cells. Celyad is confident that the…

May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing "off-the-shelf" therapies, based on…

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one…

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…

March 15, 2017 - 10 minutesmins - By External Contributor

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the…

February 13, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 3 Jan 2017

10 Hot European Biotechs to Observe in 2017 🚀

New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in…

January 3, 2017 - 5 minutesmins - By Philip Hemme

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here's a list of medical fails in biotech…

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by…

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma,…

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to…

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering